おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Cogentus Pharmaceuticals
company
About
Cogentus Pharmaceuticals is a company focused on developing prescription pharmaceutical products in North America and Europe.
- 11 - 50
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $62.50M
- Industries
- Biotechnology,Medical,Pharmaceutical
- Founded date
- Jan 1, 2006
- Number Of Employee
- 11 - 50
- Operating Status
- Close
Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$62.50M
Cogentus Pharmaceuticals has raised a total of
$62.50M
in funding over 2 rounds. Their latest funding was raised on
Dec 21, 2007 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 21, 2007 | Series C | $62.50M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Cogentus Pharmaceuticals is funded by 1 investors.
Apothecary Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
